Here's Why You Should Look Beyond NICE's Pushback on Tecfidera

The U.K.'s cost cutting agency has pushed back on Biogen's (BIIB) Tecfidera, but that shouldn't surprise you.

Feb 24, 2014 at 2:35PM

It shouldn't surprise anyone that the U.K.'s top cost watchdog, the National Institute for Health and Care Excellence, otherwise known as NICE, has balked at Biogen's (NASDAQ:BIIB) white-hot selling new oral treatment Tecfidera.

After all, this isn't new territory for MS patients in the United Kingdom. In January, Sanofi (NYSE:SNY) finally convinced regulators to pay for Aubagio, its competing oral MS therapy, after the agency had previously opted against it.

Novartis' (NYSE:NVS) oral MS drug Gilenya ran a similar gauntlet when it went up for approval in 2011. Gilenya failed to get the drug approved twice before winning reimbursement in March 2012.

In fact, NICE's action on Tecfidera should likely be viewed status quo, rather than a Tecfidera sell signal. If that's the case, investors selling Biogen on the short-term hiccup last week may end up regretting it. The stock is already back to new highs following the initial slide from $335 to less than $325 following NICE's decision on February 19th.

BIIB Chart

BIIB data by YCharts

Let's make a deal
Gilenya and Aubagio command list prices of $58,000 and $45,000 per year, respectively, but those prices were discounted significantly to win NICE's approval. A similar negotiation is likely under way between Biogen (NASDAQ:BIIB) and NICE on Tecfidera, which is priced at $55,000. As I pointed out previously, European prices may eventually be half the U.S. list price.

However, deep discounts in Europe haven't proved a stiff headwind for Gilenya, and they probably won't prove too much of a hurdle for Aubagio. Novartis (NYSE:NVS) sold $527 million worth of Gilenya last quarter, and roughly $900 million of Gilenya's $1.9 billion in sales came from outside the U.S. in 2013.

And it's not like Biogen (NASDAQ:BIIB) doesn't have plenty of experience making money in the region. The company sold $1.1 billion worth of Avonex and $700 million worth of Tysabri overseas in 2013, a lot of which came from Europe. As a result, analysts project the region may represent up to a third of Tecfidera's eventual $4 billion in peak annual sales. 

Fool-worthy final thoughts
Tecidera has been a resounding success in the U.S. and while Biogen (NASDAQ:BIIB) is tempering analyst enthusiasm by downplaying how quickly it will gain ground in Europe, it's not a stretch to assume Tecfidera will eventually become a top seller there too.

The overall market for MS treatment is growing as a larger diagnosed population shifts to these more expensive next generation therapies. Gilenya's first-to-market advantage has entrenched it as oral market share leader; however, that leadership position will be challenged this year now that Aubagio is more widely available. Looking out even further, winning NICE's eventual support  for Tecfidera may present an even bigger threat to Gilenya, and that means an even bigger opportunity for Biogen (NASDAQ:BIIB) investors.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisor's, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers